Kimball Electronics Bets on Medical Devices and Debt Paydown, Guides for 7%-9% Sales Growth in Fiscal 2027
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
Kimball Electronics (KE) reported fiscal Q4 2026 results on August 12, with net sales of $371.6 million, a 5% sequential increase, though full-year sales fell 4% to $1.431 billion. The company is betting on medical devices and its newly acquired Helvoet Polymer Technologies business to drive growth in fiscal 2027, forecasting net sales of $1.535-$1.56 billion, a 7-9% increase. Medical is expected to supply over a third of total sales. Cash from operations reached $42.4 million in the quarter, reducing total debt to $116.6 million, the lowest in over four years. However, adjusted operating income margin slipped to 4.9% from 5.2% a year earlier, and fiscal 2027 guidance projects margins of 4.4-4.7%, essentially flat. The automotive segment, still the largest at 46% of sales, declined 7% for the year. The article notes that hedge fund ownership rose from 14 to 16 funds, while short interest stands at 6.59% of float, indicating mixed market sentiment about the turnaround.
Source report
Maham Fatima Wed, September 9, 2026 at 8:23 PM PDT | 4 min read
KE -0.72%
On August 12, Kimball Electronics (NASDAQ: KE) reported fourth-quarter results for the period ended June 30, along with guidance for fiscal 2027. Net sales for the quarter came in at $371.6 million, a 5% sequential increase, with every end-market vertical posting gains. The company framed the year ahead around growth generated internally plus the added contribution from its newly acquired Helvoet Polymer Technologies business. Behind that outlook sits a full fiscal year in which total sales actually fell 4%, setting up a real tension between where Kimball Electronics has been and where it says it is going.
Cash Flow Fixes the Foundation
Cash generation was the clearest bright spot. Kimball Electronics posted $42.4 million in cash from operations during the quarter, marking ten straight quarters in which operating cash flow has stayed positive. That cash helped push total debt down to $116.6 million, the lowest level in more than four years, while the company still held $88.9 million in cash and $322.4 million of borrowing capacity. Cash Conversion Days fell to 82, the strongest reading in 17 quarters, pointing to tighter working capital management than at any point in recent memory. That balance sheet strength gave the company room to repurchase 83,000 shares for $2.1 million in the quarter and 447,000 shares for $11.9 million across the full year.
Fiscal 2027 guidance calls for net sales of $1.535 billion to $1.56 billion, a 7% to 9% increase over fiscal 2026, split between 3% to 5% organic growth and roughly $60 million in sales from the newly acquired Helvoet. Medical is expected to post percentage growth somewhere between a strong single-digit and a modest double-digit pace, and to supply upward of a third of the company's total sales in fiscal 2027, extending a shift already visible in fiscal 2026, when Medical sales rose over 10% once a prior year consigned inventory sale is stripped out.
Growth That Isn't Growing Yet
Despite the improving cash position, the top line has been shrinking. Full-year net sales fell 4% to $1.431 billion, and automotive—still Kimball Electronics' largest vertical at 46% of quarterly sales—dropped 7% for the year and 3% in the fourth quarter alone. Industrial sales excluding the divested AT&M business fell 5% both in the quarter and for the full year.
Profitability looked uneven once one-time items are stripped out:
- Adjusted operating income margin for the quarter was 4.9%, down from 5.2% a year earlier.
- Adjusted diluted earnings per share swung from a positive $0.34 in the fourth quarter of fiscal 2025 to a loss of $0.01 in the same quarter this year.
- Full-year adjusted diluted EPS slipped to $1.09 from $1.12.
Fiscal 2027 guidance calls for an adjusted operating income margin of just 4.4% to 4.7%, essentially flat to lower than the 4.6% posted in fiscal 2026, even as the company plans to spend $50 million to $60 million on capital expenditures. That mix of higher spending and guidance for margins that aren't clearly improving raises the question of how much of the promised growth reaches the bottom line.
What Wall Street Is Watching
Hedge fund ownership of Kimball Electronics rose from 14 funds to 16 funds quarter over quarter, pointing to modestly growing institutional interest. Short interest sits at 6.59% of float, a level that suggests a real but not overwhelming bear camp has built a position. The stock trades at a forward price-to-earnings ratio of 21.51 as of September 9, a multiple that assumes the fiscal 2027 growth guidance holds up. That combination of rising fund ownership and mid-single-digit short interest shows the market is still working out how much credit to give the turnaround.
The Year That Decides It
Kimball Electronics is entering fiscal 2027 with a cleaner balance sheet, less debt, more cash, and guidance for a return to top-line growth after two years of decline. Whether that growth shows up depends largely on Medical hitting its ambitious sales target and Helvoet delivering close to the $60 million in sales the company expects.
Source
Yahoo FinanceWestern